Esanik Therapeutics
Malvern, US · Delaware corporation
Founders & leadership
JM
John Mel SorensenExecutive
Reported raises · per SEC filings
Form D private placements$3.5M disclosed across 2 rounds · 2024–2026
▶$200KraisedApr 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedApr 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John Mel SorensenExecutive Officer, Director
- Offering amount
- $375K
- Amount sold
- $200K
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedNov 2024 · 4 investors · PharmaceuticalsRule 506(b)
▶$3.3MraisedNov 2024 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John Mel SorensenExecutive Officer
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Esanik Therapeutics raised?
- Esanik Therapeutics has disclosed $3.5M raised across 2 rounds.
- Where is Esanik Therapeutics headquartered?
- Esanik Therapeutics is headquartered in Malvern, US.